Contract facts
Small businessMedical Research and Development Contract Dha SBIR PH Ii, Proposal NO. H2S-0048, Titled: "GW-TT2, a New Drug Product fo… is a federal Small business award for Army Med Res Acq Activity held by Gateway Biotechnology Inc. Estimated value $1.9M ($1.9M obligated). Current period of performance ends Aug 23, 2027. Last award drew 1 bidder. Place of performance: ROOTSTOWN OH. Related solicitation HQ003420RBDST.
Medical research and development contract dha sbir ph ii, proposal no. h2s-0048, titled: "gw-tt2, a new drug product for tinnitus". Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Aug 23, 2027 (289 days remaining). Agencies typically plan 12–18 months ahead — at 9.5 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on HT942523C0071? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordGateway Biotechnology Inc — $1.3M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT942523C0071?
HT942523C0071 (Medical research and development contract dha) is a Army Med Res Acq Activity award with a potential value of $1.9M, currently held by Gateway Biotechnology Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT9425-23-C-0071?
HT9425-23-C-0071 is the dashed form of contract HT942523C0071 (Medical research and development contract dha), held by Gateway Biotechnology Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT942523C0071?
Army Med Res Acq Activity awarded HT942523C0071 to Gateway Biotechnology Inc (potential $1.9M).
Who is the incumbent on HT942523C0071?
Gateway Biotechnology Inc is the incumbent with $1.3M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 23, 2027.
When does Gateway Biotechnology Inc’s HT942523C0071 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 23, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HT942523C0071? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by contract number; task orders appear as independent rows.